Patents by Inventor Lynn MacDonald

Lynn MacDonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210051930
    Abstract: The invention provides a genetically modified non-human animal that comprises in its genome unrearranged T cell receptor variable gene loci, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified non-human animal and methods of making the same. Various methods of using the genetically modified non-human animal are also provided.
    Type: Application
    Filed: October 27, 2020
    Publication date: February 25, 2021
    Inventors: Lynn Macdonald, Andrew J. Murphy, John McWhirter, Naxin Tu, Vera Voronina, Cagan Gurer, Karolina Meagher, Sean Stevens
  • Publication number: 20210029978
    Abstract: Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Ig? light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Ig? light chains, in whole or in part, that are encoded by human Ig? light chain-encoding sequences inserted into an endogenous Ig? light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.
    Type: Application
    Filed: September 24, 2020
    Publication date: February 4, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Chunguang Guo, Faith Harris, Vera Voronina, John McWhirter, Natasha Levenkova, Lynn Macdonald, Naxin Tu, Andrew J. Murphy
  • Patent number: 10905109
    Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: February 2, 2021
    Assignee: Regeneren Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow
  • Patent number: 10905108
    Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: February 2, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow
  • Publication number: 20210007781
    Abstract: A soft tapping device for preparing a bone hole that includes a substantially cylindrical insert that is sized to enter into a compressed woven retention device. The substantially cylindrical insert has protrusions that are adaptable to expand portions of a compressed woven retention device inside the bone hole. The substantially cylindrical insert is also configured to exit from the compressed woven retention device without changing the expanded portions of the compressed woven retention device.
    Type: Application
    Filed: February 10, 2020
    Publication date: January 14, 2021
    Inventors: Francis Patrick Magee, Robert Luzzi, Jeffrey P. Radziunas, Lynn MacDonald
  • Patent number: 10881085
    Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises (a) a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of a heavy chain constant region gene sequence, and (b) replacement of one or all endogenous VH, DH and JH gene segments with at least one unrearranged light chain variable (VL) gene segment and at least one unrearranged light chain joining (JL) gene segment capable of recombining to form a rearranged light chain variable region (VL/JL) nucleotide sequence operably linked to the heavy chain constant region gene sequence comprising a deletion in the CH1 gene and/or insertion of a genetically engineered single rearranged light chain, wherein the mouse is capable of expressing a functional IgM, single domain antigen binding proteins, e.g., VL-single domain binding proteins, and a genetically engineered rearranged light chain.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: January 5, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy
  • Patent number: 10869466
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of the human immune system are provided.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: December 22, 2020
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens
  • Publication number: 20200375159
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Application
    Filed: August 6, 2020
    Publication date: December 3, 2020
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens, Yingzi Xue
  • Publication number: 20200377618
    Abstract: Methods for making, identifying, isolating and/or making binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Exemplary binding proteins specific to small molecules are also provided.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 3, 2020
    Inventors: Robert Babb, Ashique Rafique, Tammy T. Huang, Ergang Shi, Lynn Macdonald, Andrew J. Murphy
  • Publication number: 20200375160
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Application
    Filed: August 12, 2020
    Publication date: December 3, 2020
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens
  • Publication number: 20200370054
    Abstract: A non-human animal (e.g., a rodent) model for diseases associated with a C9ORF72 heterologous hexanucleotide repeat expansion sequence is provided, which non-human animal comprises a heterologous hexanucleotide repeat (GGGGCC) in an endogenous C9ORF72 locus. A non-human animal disclosed herein comprising a heterologous hexanucleotide repeat expansion sequence comprising at least one instance, e.g., repeat, of a hexanucleotide (GGGGCC) sequence may further exhibit a characteristic and/or phenotype associated with one or more neurodegenerative disorders (e.g., amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD), etc.). Methods of identifying therapeutic candidates that may be used to prevent, delay or treat one or more neurodegenerative (e.g., amyotrophic lateral sclerosis (ALS, also referred to as Lou Gehrig's disease) and frontotemporal dementia (FTD)) are also provided.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 26, 2020
    Inventors: David Heslin, Roxanne Ally, Chia-Jen Siao, Ka-Man Venus Lai, David M. Valenzuela, Chunguang Guo, Michael LaCroix-Fralish, Lynn Macdonald, Aarti Sharma-Kanning, Daisuke Kajimura, Gustavo Droguett, David Frendewey, Alexander O. Mujica
  • Patent number: 10820582
    Abstract: Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Ig? light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Ig? light chains, in whole or in part, that are encoded by human Ig? light chain-encoding sequences inserted into an endogenous Ig? light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: November 3, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Chunguang Guo, Faith Harris, Vera Voronina, John McWhirter, Natasha Levenkova, Lynn Macdonald, Naxin Tu, Andrew J. Murphy
  • Patent number: 10820581
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8?, CD8?), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: November 3, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Vera Voronina, Cagan Gurer
  • Publication number: 20200339672
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Application
    Filed: July 10, 2020
    Publication date: October 29, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
  • Publication number: 20200315149
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized coagulation factor XII (F12) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized F12 locus express a human coagulation factor XII protein or a chimeric coagulation factor XII protein, fragments of which are from human coagulation factor XII. Methods are provided for using such non-human animals comprising a humanized F12 locus to assess in vivo efficacy of human-coagulation-factor-XII-targeting reagents such as nuclease agents designed to target human F12. A short isoform of F12 that is produced locally in the brain, and methods of using the short isoform, are also provide.
    Type: Application
    Filed: April 2, 2020
    Publication date: October 8, 2020
    Inventors: Yajun Tang, Dan Chalothorn, Lyndon Mitnaul, Lori Morton, Daria Zamolodchikov, Nicole Alessandri-Haber, Lynn Macdonald
  • Patent number: 10787522
    Abstract: Methods for making, identifying, isolating and/or making binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Exemplary binding proteins specific to small molecules are also provided.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 29, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, Ashique Rafique, Tammy T. Huang, Ergang Shi, Lynn Macdonald, Andrew J. Murphy
  • Publication number: 20200299414
    Abstract: Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Protein comprising two or three or four or more different heavy chain variable domains that lack an immunoglobulin variable domain are provided. Proteins comprising two or three or four or more different heavy chain variable domains that associate with the same immunoglobulin light chain variable domain are also provided.
    Type: Application
    Filed: March 4, 2020
    Publication date: September 24, 2020
    Inventors: George D. Yancopoulos, Nicholas J. Papadopoulos, Neil Stahl, Samuel Davis, Andrew J. Murphy, Lynn Macdonald
  • Patent number: 10779520
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: September 22, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens, Yingzi Xue
  • Publication number: 20200288684
    Abstract: Genetically modified mice and methods and compositions for making and using the same are provided, wherein the genetic modification comprises humanization of an Fc?RI protein.
    Type: Application
    Filed: December 20, 2019
    Publication date: September 17, 2020
    Inventors: Andrew J. Murphy, Lynn Macdonald, Cagan Gurer, Karolina A. Meagher, Naxin Tu
  • Publication number: 20200281175
    Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.
    Type: Application
    Filed: April 15, 2020
    Publication date: September 10, 2020
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow, John McWhirter